Meeder Asset Management’s ADMA Biologics ADMA Stock Holding History

Meeder Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.6K	Sell	8,913 -846	-9%	-$7.71K	﹤0.01%	403
2026 Q1	$87.9K	Sell	9,759 -702	-7%	-$11.1K	0.01%	379
2025 Q4	$191K	Buy	+10,461	New	+$176K	0.01%	273
2024 Q4	–	Sell	-454	Closed	-$9.07K	–	901
2024 Q3	$9.07K	Buy	+454	New	+$7.06K	﹤0.01%	639
2021 Q4	–	Sell	-1,008	Closed	-$1K	–	1109
2021 Q3	$1K	Hold	1,008	–	–	﹤0.01%	2268
2021 Q2	$2K	Hold	1,008	–	–	﹤0.01%	2175
2021 Q1	$1K	Buy	+1,008	New	+$2.31K	﹤0.01%	2164
2020 Q2	–	Sell	-2,202	Closed	-$6K	–	2014
2020 Q1	$6K	Buy	2,202 +710	+48%	+$2.45K	﹤0.01%	1695
2019 Q4	$6K	Sell	1,492 -30	-2%	-$131	﹤0.01%	1700
2019 Q3	$7K	Buy	1,522 +233	+18%	+$974	﹤0.01%	1628
2019 Q2	$5K	Buy	1,289 +303	+31%	+$1.34K	﹤0.01%	1648
2019 Q1	$4K	Buy	986 +157	+19%	+$555	﹤0.01%	1424
2018 Q4	$2K	Sell	829 -251	-23%	-$1.24K	﹤0.01%	1557
2018 Q3	$7K	Buy	1,080 +684	+173%	+$3.94K	﹤0.01%	1233
2018 Q2	$1.79K	Buy	+396	New	+$1.97K	﹤0.01%	1430

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Meeder Asset Management's ADMA Position: Q2 2026 in Review

Meeder Asset Management reduced its ADMA Biologics (ADMA) stake by 8.7% in Q2 2026, selling an estimated $7.71K and leaving 8,913 shares worth $74.6K. The position accounts for ﹤0.01% of the portfolio, ranked #403.

Meeder Asset Management first reported a position in ADMA in Q2 2018 and has held it in 15 quarters since. The position peaked at $191K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Meeder Asset Management held 8,913 shares of ADMA Biologics worth $74.6K as of Q2 2026.
Meeder Asset Management sold 846 ADMA Biologics shares in Q2 2026, an estimated $7.71K.
ADMA Biologics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #403 holding.
Meeder Asset Management first reported a position in ADMA Biologics in Q2 2018 and has held it in 15 quarters since.
Meeder Asset Management's ADMA Biologics position peaked at $191K in Q4 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.